NEWS IN BRIEF

Paracetamol batches recalled after fungal contamination

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Shidlovski)
(Image: Getty/Shidlovski)

Related tags M&A Pharmachem Mhra Paracetamol Recall

The MHRA announces recall of paracetamol tablets, after certain products were found to be discoloured due to the presence of fungi.

M&A Pharmachem, a UK-based producer of complex molecules and OTC products, is recalling two batches of paracetamol 500mg tablets, each containing 12 pots of 1,000 tablets.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) stated that only a ‘small number’ of pots from each batch had been found to be contaminated.

Inspections of the affected tablets revealed that fungi contaminating the products were Penicillium citrinium​ and Penicillium brevicompactum​.

The agency noted that the discoloration of tablets meant that it is ‘unlikely’ that any tablets had reached the patient level.

Any healthcare professionals or wholesalers that had received products from the affected batches were advised to stop supplying the product before then quarantining and returning the stock to suppliers.

M&A Pharmachem distributed the first batch in September 2018 and the second in March 2019, with expiry dates of June 2023 and October 2023, respectively.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars